Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of HZ-A-018 in adults with chronic spontaneous urticaria
CTR20261831Phase 2Active
- Sponsor
- Hezheng Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HZ-A-018 in chronic idiopathic urticaria (CIU), sponsored by Hezheng Pharma. Started Jun 2026; status: active.
02
Drugs
HZ-A-018
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20261831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261831.